SCHEMBL1950011

SCHEMBL1950011

CC1(C)O[C@@H]2[C@@H](CN(C(=O)O)S(N)(=O)=O)C[C@@H](n3cnc4c(Cl)ncnc43)[C@@H]2O1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PI4KA P42356 1/20 0.37
▸ PI4K2B Q8TCG2 1/20 0.37
▸ PI4K2A Q9BTU6 1/20 0.37
▸ PI4KB Q9UBF8 1/20 0.37
▸ AHCY P23526 3/20 0.36
▸ ADORA2B P29275 1/20 0.34
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ HNMT P50135 1/20 0.33
▸ P2RX1 P51575 1/20 0.33
▸ P2RX3 P56373 1/20 0.33
▸ P2RX4 Q99571 1/20 0.33
▸ TRDMT1 O14717 1/20 0.32
▸ AMD1 P17707 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17889817 1.00 RXFP1 (0.38) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL1802098 0.89 RXFP1 (0.37) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL1945890 0.82 PI4KA (0.54) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL17889809 0.81 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBAHCY
SCHEMBL1799630 0.81 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBAHCY
SCHEMBL23776486 0.81 PI4KA (0.42) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL5319686 0.81 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBAHCY
SCHEMBL5318875 0.81 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBAHCY
SCHEMBL6467117 0.81 RXFP1 (0.40) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL18512602 0.80 AHCY (0.47) RXFP1PI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 — — US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 — — US disclosed
EP-1848718-B1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARM INC (US) 2012-08-01 — — EP disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 RXFP1 3880/4885PI4KA 1455/4885PI4K2B 2027/4885
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES ECE1, RNASE1, RCE1 RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885
US-20210070798-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback